Search

Your search keyword '"C. Bulletti"' showing total 165 results
Start Over Author "C. Bulletti"
165 results on '"C. Bulletti"'

1. Reproductive (epi)genetics

Author

C. Lynch, N. Tee, H. Rouse, A. Gordon, L. Sati, C. Zeiss, B. Soygur, I. Bassorgun, E. Goksu, R. Demir, J. McGrath, M. L. Groendahl, L. Thuesen, A. N. Andersen, A. Loft, J. Smitz, T. Adriaenssens, J. Vikesa, R. Borup, E. Mersy, N. Kisters, M. V. E. Macville, J. J. M. Engelen, S.-E. N. N. Consortium, P. P. C. A. Menheere, J. P. Geraedts, A. B. C. Coumans, S. G. M. Frints, T. Aledani, S. Assou, S. Traver, O. Ait-ahmed, H. Dechaud, S. Hamamah, E. Mizutani, N. Suzumori, C. Sugiyama, Y. Hattori, T. Sato, H. Ando, Y. Ozaki, M. Sugiura-Ogasawara, M. Wissing, S. G. Kristensen, C. Y. Andersen, A. L. Mikkelsen, T. Hoest, A. Velthut-Meikas, J. Simm, M. Metsis, A. Salumets, S. Palini, L. Galluzzi, S. De Stefani, M. Primiterra, D. Wells, M. Magnani, C. Bulletti, P. H. Vogt, P. Frank-Herrmann, U. Bender, T. Strowitzki, B. Besikoglu, P. Heidemann, L. Wunsch, M. Bettendorf, L. Jelinkova, S. Vilimova, M. Kosarova, P. Sebek, E. Volemanova, M. Kruzelova, J. Civisova, L. Svobodova, V. Sobotka, T. Mardesic, C. van de Werken, M. A. Santos, C. Eleveld, J. S. E. Laven, E. B. Baart, L. Y. Pylyp, L. A. Spinenko, V. D. Zukin, J. Perez-Sanz, R. Matorras, J. Arluzea, J. Bilbao, N. Gonzalez-Santiago, N. Yeh, A. Koff, A. Barlas, Y. Romin, K. Manova-Todorova, C. D. l. Hoz, A. L. Mauri, A. M. Nascimento, L. D. Vagnini, C. G. Petersen, J. Ricci, F. C. Massaro, M. Cavagna, A. Pontes, J. B. A. Oliveira, R. L. R. Baruffi, J. G. Franco, E. X. Wu, S. Ma, M. Parriego, M. Sole, M. Boada, B. Coroleu, A. Veiga, G. Kakourou, M. Poulou, C. Vrettou, A. Destouni, J. Traeger-Synodinos, E. Kanavakis, A. N. Yatsenko, A. P. Georgiadis, M. M. McGuire, M. Zorrilla, K. D. Bunce, D. Peters, A. Rajkovic, M. Olszewska, M. Kurpisz, A. Z. A. Gilbertson, C. S. Ottolini, M. C. Summers, K. Sage, A. H. Handyside, A. R. Thornhill, D. K. Griffin, M. K. Chung, J. W. Kim, J. H. Lee, H. J. Jeong, M. H. Kim, M. J. Ryu, S. J. Park, H. Y. Kang, H. S. Lee, B. Zimmermann, M. Banjevic, M. Hill, P. Lacroute, M. Dodd, S. Sigurjonsson, P. Lau, D. Prosen, N. Chopra, A. Ryan, M. Hall, S. McAdoo, Z. Demko, B. Levy, M. Rabinowitz, A. Vereczeky, Z. S. Kosa, S. Savay, M. Csenki, L. Nanassy, B. Dudas, Z. S. Domotor, D. Debreceni, A. Rossi, J. R. Alegretti, J. Cuzzi, M. Bonavita, M. Tanada, P. Matunaga, P. Fettback, M. B. Rosa, V. Maia, P. Hassun, E. L. A. Motta, M. Piccolomini, C. Gomes, B. Barros, M. Nicoliello, T. Criscuolo, E. Miyadahira, D. Montjean, M. Benkhalifa, I. Berthaut, J. F. Griveau, K. Morcel, A. Bashamboo, K. McElreavey, C. Ravel, C. Rubio, L. Rodrigo, E. Mateu, A. Mercader, V. Peinado, P. Buendia, M. Milan, A. Delgado, N. Al-Asmar, L. Escrich, I. Campos-Galindo, S. Garcia-Herrero, M. E. Poo, P. Mir, C. Simon, A. Reyes-Engel, M. Cortes-Rodriguez, A. Lendinez, B. Perez-Nevot, A. R. Palomares, M. R. Galdon, A. Ruberti, M. G. Minasi, A. Biricik, A. Colasante, D. Zavaglia, E. Iammarrone, F. Fiorentino, E. Greco, N. Demir, S. Ozturk, B. Sozen, R. Morales, B. Lledo, J. A. Ortiz, J. Ten, J. Llacer, R. Bernabeu, M. Nagayoshi, A. Tanaka, I. Tanaka, H. Kusunoki, S. Watanabe, S. G. Temel, C. Beyazyurek, G. C. Ekmekci, F. Aybar, C. Cinar, S. Kahraman, S. Nordqvist, K. Karehed, H. Akerud, M. Gultomruk, P. Tulay, N. Findikli, E. Yagmur, G. Karlikaya, U. Ulug, M. Bahceci, M. F. Bargallo, M. R. Arevalo, M. M. Salat, I. V. Barbat, J. T. Lopez, M. E. Algam, A. B. Boluda, G. C. de Oya, E. N. Tolmacheva, A. A. Kashevarova, N. A. Skryabin, I. N. Lebedev, E. Semaco, A. Belo, M. Riboldi, L. Luz, N. Nobrega, R. Mazetto, J. A. Alegretti, M. Bibancos, P. Serafini, J. Neupane, M. Vandewoestyne, B. Heindryckx, T. Deroo, Y. Lu, S. Ghimire, S. Lierman, C. Qian, D. Deforce, P. De Sutter, T. Viloria, J. M. Martinez-Jabaloyas, M. Gil-Salom, A. Capalbo, N. Treff, D. Cimadomo, X. Tao, K. Ferry, F. M. Ubaldi, L. Rienzi, R. T. Scott, N. Katzorke, H. P. Vogt, A. Hehr, C. Gassner, B. Paulmann, Z. Kowalzyk, M. Klatt, S. Krauss, D. Seifert, B. Seifert, U. Hehr, M. Lobascio, M. T. Varricchio, P. Rubino, S. Bono, R. P. Cotarelo, L. Spizzichino, A. Colicchia, P. Giannini, M. Suhorutshenko, and K. Rosenstein-Tamm

Subjects
Genetics, Reproductive Medicine, Rehabilitation, Obstetrics and Gynecology, Biology
Published
2013
Full Text
View/download PDF

2. POSTER VIEWING SESSION - EMBRYOLOGY

Author

S. Fourati Ben Mustapha, M. Khrouf, K. Kacem Ben Rejeb, H. Elloumi Chaabene, G. Merdassi, D. Wahbi, M. Ben Meftah, F. Zhioua, A. Zhioua, A. Azzarello, T. Host, A. L. Mikkelsen, C. P. Theofanakis, V. Dinopoulou, D. Mavrogianni, G. A. Partsinevelos, P. Drakakis, K. Stefanidis, A. Bletsa, D. Loutradis, L. Rienzi, A. Cobo, A. Paffoni, C. Scarduelli, A. Capalbo, N. Garrido, J. Remohi, G. Ragni, F. M. Ubaldi, R. Herrer, M. Quera, E. GIL, J. Serna, M. L. Grondahl, J. Bogstad, I. E. Agerholm, J. G. Lemmen, U. Bentin-Ley, P. Lundstrom, U. S. Kesmodel, M. Raaschou-Jensen, S. Ladelund, L. Guzman, C. Ortega, F. K. Albuz, R. B. Gilchrist, P. Devroey, J. Smitz, M. De Vos, M. Bielanska, M. C. Leveille, E. Borghi, M. C. Magli, M. J. Figueroa, G. Mascaretti, A. P. Ferraretti, L. Gianaroli, E. Szlit, F. Leocata Nieto, G. Maggiotto, G. Arenas, N. Tarducci Bonfiglio, A. Ahumada, R. Asch, R. Sciorio, N. Dayoub, J. Thong, S. Pickering, J. Ten, M. A. Carracedo, J. Guerrero, A. Rodriguez-Arnedo, J. Llacer, R. Bernabeu, C. Tatone, T. Heizenrieder, G. Di Emidio, P. Treffon, T. Seidel, U. Eichenlaub-Ritter, S. S. Cortezzi, E. C. Cabral, C. R. Ferreira, M. G. Trevisan, R. C. S. Figueira, D. P. A. F. Braga, M. N. Eberlin, A. Iaconelli Jr., E. Borges Jr., A. Zabala, T. Pessino, L. Blanco, G. Rey Valzacchi, F. Leocata, F. Vanden Meerschaut, B. Heindryckx, C. Qian, D. Deforce, L. Leybaert, P. De Sutter, M. De las Heras, J. L. De Pablo, B. Navarro, J. A. Agirregoikoa, G. Barrenetxea, M. Cruz, I. Perez-Cano, B. Gadea, J. Herrero, M. Martinez, M. Roldan, M. Munoz, A. Pellicer, M. Meseguer, N. Galindo, F. Scarselli, E. Alviggi, A. Colasante, M. G. Minasi, P. Rubino, M. Lobascio, S. Ferrero, K. Litwicka, M. T. Varricchio, P. Giannini, P. Piscitelli, G. Franco, D. Zavaglia, Z. P. Nagy, E. Greco, F. Urner, D. Wirthner, F. Murisier, P. Mock, M. Germond, B. Amorocho Llanos, G. Calderon, D. Lopez, L. Fernandez, M. Nicolas, J. Landeras, S. L. Finn-Sell, R. Leandri, T. P. Fleming, N. S. Macklon, Y. C. Cheong, J. J. Eckert, J. H. Lee, Y. J. Jung, H. K. Hwang, A. Kang, S. J. An, J. Y. Jung, H. C. Kwon, S. J. Lee, S. Palini, L. Zolla, S. De Stefani, V. Scala, A. D'Alessandro, V. Polli, P. Rocchi, A. Tiezzi, E. Pelosi, L. Dusi, C. Bulletti, R. Fadini, M. Lain, M. Mignini Renzini, F. Brambillasca, G. Coticchio, M. Merola, M. C. Guglielmo, M. Dal Canto, R. Figueira, A. S. Setti, K. C. Worrilow, C. D. Uzochukwu, S. Eid, S. Le Gac, T. C. Esteves, F. van Rossem, A. van den Berg, M. Boiani, E. Kasapi, Y. Panagiotidis, M. Goudakou, A. Papatheodorou, T. Pasadaki, N. Prapas, Y. Prapas, P. Vanderzwalmen, S. Norasing, P. Atchajaroensatit, W. Tawiwong, O. Thepmanee, S. Saenlao, J. Aojanepong, P. Hunsajarupan, K. Sajjachareonpong, P. Punyatanasakchai, S. Maneepalviratn, U. Jetsawangsri, A. Tejera, I. Rubio, J. L. Romero, V. Nordhoff, S. Schlatt, A. N. Schuring, L. Kiesel, S. Kliesch, R. Azambuja, L. Okada, V. Lazzari, L. Dorfman, J. Michelon, M. Badalotti, F. Badalotti, A. Petracco, C. Schwarzer, K. Versieren, I. De Croo, S. Lierman, W. De Vos, E. Van den Abbeel, J. Gerris, I. Milacic, D. Borogovac, M. Veljkovic, B. Arsic, D. Jovic Bojovic, D. Lekic, D. Pavlovic, E. Garalejic, D. F. Albertini, E. De Ponti, F. Sanges, R. Talevi, L. Papini, V. Mollo, L. F. Rienzi, R. Gualtieri, C. Orteg, J. Choi, H. Lee, S. Ku, S. Kim, Y. Choi, J. Kim, S. Moon, E. Demilly, S. Assou, S. Moussaddykine, H. Dechaud, S. Hamamah, T. Takisawa, M. Doshida, H. Hattori, Y. Nakamura, T. Kyoya, Y. Shibuya, Y. Nakajo, A. Tasaka, M. Toya, K. Kyono, S. Novo, O. Penon, R. Gomez, L. Barrios, M. Duch, J. Santalo, J. Esteve, C. Nogues, J. A. Plaza, L. Perez-Garcia, E. Ibanez, S. Chavez, K. Loewke, B. Behr, R. Reijo Pera, S. Huang, H. Wang, Y. Soong, C. Chang, T. Okimura, M. Kuwayama, C. Mori, M. Morita, K. Uchiyama, F. Aono, K. Kato, Y. Takehara, O. Kato, M. Minasi, V. Casciani, L. Arizzi, C. Mencacci, C. Piscitelli, F. Cucinelli, A. Tocci, E. Wydooghe, L. Vandaele, J. Dewulf, A. Van Soom, J. H. Moon, W. Y. Son, A. Mahfoudh, S. Henderson, S. G. Jin, E. Shalom-Paz, M. Dahan, H. Holzer, K. Mahmoud, C. Triki-Hmam, K. Terras, T. Hfaiedh, M. H. Ben Aribia, H. Otsubo, A. Egashira, K. Tanaka, T. Matsuguma, M. Murakami, K. Murakami, M. Otsuka, N. Yoshioka, Y. Araki, T. Kuramoto, J. G. Smit, M. D. Sterrenburg, M. J. C. Eijkemans, H. G. Al-Inany, M. A. F. M. Youssef, F. J. M. Broekmans, K. Willoughby, L. DiPaolo, L. Deys, A. Lagunov, S. Amin, M. Faghih, E. Hughes, M. Karnis, F. Ashkar, W. A. King, M. S. Neal, I. Antonova, L. Veleva, L. Petkova, A. Shterev, C. Nogales, E. Martinez, M. Ariza, D. Cernuda, M. Gaytan, A. Linan, A. Guillen, F. Bronet, V. Cottin, D. Fabian, F. Allemann, A. Koller, J. C. Spira, D. Agudo, M. Martinez-Burgos, A. Arnanz, N. Basile, A. Rodriguez, Y. S. Cho, M. Filioli Uranio, B. Ambruosi, M. S. Paternoster, P. Totaro, A. M. Sardanelli, M. E. Dell'Aquila, U. Zollner, T. Hofmann, K. P. Zollner, B. Kovacic, P. Roglic, V. Vlaisavljevic, M. Sole, M. Boada, B. Coroleu, A. Veiga, G. Martiny, M. Molinari, A. Revelli, N. M. Chimote, M. Chimote, B. Mehta, N. N. Chimote, N. Sheikh, N. Nath, A. Mukherjee, K. Rakic, M. Reljic, H. J. Ingerslev, K. Kirkegaard, J. Hindkjaer, I. Agerholm, H. Kitasaka, N. Fukunaga, R. Nagai, T. Yoshimura, F. Tamura, K. Kitamura, N. Hasegawa, K. Nakayama, M. Katou, F. Itoi, E. Asano, N. Deguchi, K. Ooyama, Y. Hashiba, Y. Asada, M. Michaeli, N. Rotfarb, E. Karchovsky, O. Ruzov, R. Atamny, K. Slush, O. Fainaru, A. Ellenbogen, S. Chekuri, T. Chaisrisawatsuk, P. Chen, M. Pangestu, S. Jansen, S. Catt, E. Molinari, C. Racca, C. Ryu, S. Kang, J. Lee, D. Chung, S. Roh, H. Chi, Y. Yokota, M. Yokota, H. Yokota, S. Sato, M. Nakagawa, M. Komatsubara, M. Makita, K. Oyama, K. Naruse, S. Kilani, M. G. Chapman, M. Kwik, M. Chapman, S. Guven, E. Odaci, O. Yildirim, C. Kart, M. A. Unsal, E. Yulug, E. Isachenko, R. Maettner, E. Strehler, V. Isachenko, K. Hancke, R. Kreienberg, K. Sterzik, X. Y. Zheng, L. N. Wang, P. Liu, J. Qiao, F. Inoue, M. Dashtizad, H. Wahid, Y. Rosnina, M. Daliri, H. Hajarian, M. Akbarpour, O. Abbas Mazni, K. Knez, T. Tomaevic, E. Vrtacnik Bokal, B. Zorn, I. Virant Klun, M. Koster, J. Liebenthron, A. Nicolov, K. van der Ven, H. van der Ven, M. Montag, M. Fayazi, M. Salehnia, M. Beigi Boroujeni, B. Khansarinejad, K. Deignan, G. Emerson, E. Mocanu, J. J. Wang, M. Andonov, E. Linara, K. K. Ahuja, S. Nachef, F. F. Pasqualotto, E. Pasqualotto, C. C. Chang, D. P. Bernal, T. A. Elliott, D. B. Shapiro, A. A. Toledo, K. Economou, S. Davies, M. Argyrou, S. Doriza, P. Sisi, M. Moschopoulou, A. Karagianni, C. Mendorou, N. Polidoropoulos, C. Papanicopoulos, P. Stefanis, C. Karamalegos, H. Cazlaris, M. Koutsilieris, M. Mastrominas, S. Gotts, A. Doshi, J. Harper, P. Serhal, A. Borini, O. Guzeloglu-Kayisli, V. Bianchi, E. Seli, M. Lappi, M. A. Bonu, S. Mizuta, H. Hashimoto, Y. Kuroda, Y. Matsumoto, Y. Mizusawa, S. Ogata, S. Yamada, S. Kokeguchi, Y. Noda, M. Shiotani, M. Stojkovic, M. Ilic, N. Markovic, P. Stojkovic, G. Feng, B. Zhang, H. Zhou, L. Zhou, X. Gan, X. Qin, J. Shu, F. Wu, I. Molina Botella, E. Lazaro Ibanez, A. Debon Aucejo, J. Pertusa, P. J. Fernandez Colom, C. Li, Y. Zhang, Y. Cui, H. Zhao, J. Liu, J. B. A. Oliveira, C. G. Petersen, A. L. Mauri, F. C. Massaro, L. F. I. Silva, J. Ricci, M. Cavagna, A. Pontes, L. D. Vagnini, R. L. R. Baruffi, J. G. Franco Jr., V. Felipe, M. Vilela, M. Tiveron, C. Lombardi, M. I. Viglierchio, G. Marconi, V. Rawe, P. L. Wale, D. K. Gardner, K. Nakagawa, R. Sugiyama, Y. Nishi, Y. Kuribayashi, H. Jyuen, E. Yamashiro, A. Shirai, M. Inoue, O. Hovatta, V. Tohonen, J. Inzunza, L. Parmegiani, G. E. Cognigni, S. Bernardi, W. Ciampaglia, F. E. Infante, C. Tabarelli de Fatis, P. Pocognoli, A. Arnone, A. M. Maccarini, E. Troilo, M. Filicori, P. Radwan, I. Polac, M. Borowiecka, M. Bijak, and M. Radwan

Subjects
medicine.medical_specialty, Reproductive Medicine, Embryology, Rehabilitation, medicine, Obstetrics and Gynecology, Medical physics, Session (computer science), Psychology
Published
2011
Full Text
View/download PDF

3. Andrology (Male Fertility, Spermatogenesis)

Author

Y. Matsumoto, S. Goto, H. Hashimoto, S. Kokeguchi, M. Shiotani, H. Okada, P. Cohen - Bacrie, A. Hazout, S. Belloc, J. De Mouzon, Y. Menezo, M. Dumont, A. M. Junca, M. Cohen-Bacrie, S. Alvarez, F. Olivennes, N. Prisant, M. Weltin, W. Geissler, C. Clussmann, T. Strowitzki, W. Eggert-Kruse, Y. Endou, Y. Fjii, H. Motoyama, F. Q. Quintana, Z. L. Zaloa Larreategui, I. P. Iratxe Penalba, S. O. Sara Ortega, M. M. Monica Martin, G. Q. Guillermo Quea, J. S. Jose Serna, M. G. Showell, J. Brown, A. Yazdani, M. T. Stankiewicz, R. J. Hart, C. Zumoffen, M. J. Munuce, A. Caille, S. Ghersevich, A. M. Lendinez, B. Perez-Nevot, A. R. Palomares, A. Serrano Garballo, A. Rodriguez, A. Reche, A. Mayor-Olea, M. Ruiz-Galdon, A. Reyes-Engel, J. Mendiola, N. Jorgensen, A. M. Andersson, A. M. Calafat, J. B. Redmon, E. Z. Drobnis, C. Wang, A. Sparks, S. W. Thurston, F. Liu, S. H. Swan, A. C. Tarasconi, B. V. Tarasconi, D. V. Tarasconi, E. M. V. Silva, Y. Fujii, I. Crha, J. Pribyl, P. Skladal, J. Zakova, P. Ventruba, M. Pohanka, G. De La Fuente, A. Pacheco, J. A. G. Velasco, A. Requena, A. Pacheco Castro, M. San Celestino Carchenilla, R. Salvanes, A. Arnanz, C. Balmori, A. Pellicer, J. A. Garcia-Velasco, T. Ishikawa, M. Fujisawa, S. Kranz, K. Hersemeyer, A. Hentrich, H. R. Tinneberg, L. Konrad, L. Simon, D. Lutton, J. McManus, S. E. M. Lewis, S. Rubio, P. Simon Sanjurjo, S. Lewis, J. Buzzi, A. Valcarcel, E. Lombardi, R. Oses, V. Rawe, E. Young, A. Magendzo, S. Lizama, G. Duque, A. Mackenna, A. Monqaut, C. Zavaleta, G. Lopez, R. Lafuente, M. Brassesco, R. Condorelli, S. La Vignera, S. La Rosa, N. Barone, E. Vicari, S. Bellanca, R. D'Agata, A. E. Calogero, M. Enciso, M. Iglesias, I. Galan, A. Gosalvez, J. Gosalvez, M. Curaba, J. Poels, A. Van Langendonckt, J. Donnez, C. Wyns, M. Garcez, M. Salvador, E. B. Pasqualotto, D. P. A. F. Braga, E. Borges, F. F. Pasqualotto, T. Aoki, R. C. S. Figueira, L. G. L. Maldonado, A. Iaconelli, R. Frassini, J. Mandelli, A. S. Setti, S. S. Cortezzi, M. Di Mauro, N. Burrello, J. Kashir, C. Jones, C. Young, M. Ruas, P. Grasa, K. Rietdorf, E. Heytens, B. Heindryckx, S. Y. Yoon, R. A. Fissore, C. M. Deane, D. Nikiforaki, S. T. Tee, P. de Sutter, J. Parrington, K. Coward, L. Visser, G. H. Westerveld, S. K. M. van Daalen, F. van der Veen, M. P. Lombardi, S. Repping, S. Cubillos, S. Sanchez, J. Pedraza, G. Charria, H. Aparicio, A. Gongora, F. Caldino, S. Cuneo, J. P. Ou, W. E. Zhao, Y. F. Liu, Y. W. Xu, C. Q. Zhou, N. Al-Asmar Pinar, V. Peinado, J. Gruhn, M. Susiarjo, M. Gil-Salom, J. M. Martinez-Jabaloyas, J. Remohi, C. Rubio, T. Hassold, N. Al-Asmar, L. Rodrigo, T. J. Hassold, M. Bungum, N. Forsell, A. Giwercman, I. Amiri, N. Sheikh, R. Najafi, M. Godarzi, M. Farimani, H. Makukh, M. Tyrkus, D. Zastavna, A. Nakonechnuy, S. S. Khayat, L. V. Schileiko, L. F. Kurilo, S. Garcia-Herrero, N. Garrido, J. A. Martinez-Conejero, L. Romany, M. Meseguer, B. Dorphin, M. Lefevre, C. Gout, P. Oger, C. Yazbeck, N. Rougier, S. De Stefani, V. Scala, S. Benedetti, M. C. Tagliamonte, E. Zavagnini, S. Palini, C. Bulletti, F. Canestrari, N. Subiran, F. M. Pinto, M. L. Candenas, E. Agirregoitia, J. Irazusta, E. M. Cha, J. H. Lee, I. H. Park, K. H. Lee, M. H. Kim, M. S. Jensen, C. Rebordosa, A. M. Thulstrup, G. Toft, H. T. Sorensen, J. P. Bonde, T. B. Henriksen, J. Olsen, L. Bosco, M. Speciale, M. Manno, N. Amireh, M. C. Roccheri, E. Cittadini, P. Wu, Y. M. Lee, H. W. Chen, C. R. Tzeng, J. Llacer, J. Ten, B. Lledo, A. Rodriguez-Arnedo, R. Morales, R. Bernabeu, A. Garcia-Peiro, J. Martinez-Heredia, M. Oliver-Bonet, J. Ribas, C. Abad, M. J. Amengual, J. Navarro, J. Benet, C. Moutou, N. Gardes, J. C. Nicod, N. Becker, M. P. Bailly, I. Galland, O. Pirello, C. Rongieres, C. Wittemer, S. Viville, W. Elmahaishi, B. Smith, A. Doshi, P. Serhal, J. C. Harper, C. Rennemeier, U. Kammerer, J. Dietl, P. Staib, K. Elgmati, M. Nomikos, M. Theodoridou, B. Calver, K. Swann, F. A. Lai, I. Georgiou, L. Lazaros, N. Xita, A. Kaponis, N. Plachouras, E. Hatzi, K. Zikopoulos, F. Ferfouri, P. Clement, D. Molina Gomes, M. Albert, M. Bailly, R. Wainer, J. Selva, F. Vialard, T. Takisawa, K. Usui, T. Kyoya, Y. Shibuya, H. Hattori, Y. Sato, M. Ota, K. Kyono, P. C. Chiu, K. K. Lam, C. L. Lee, M. K. Chung, V. W. Huang, W. S. O, F. Tang, P. C. Ho, W. S. Yeung, C. H. Kim, J. Y. Lee, S. H. Kim, C. S. Suh, Y. K. Shin, Y. J. Kang, J. H. Jung, C. Y. Cha, E. S. Hwang, T. Mukaida, M. Nagaba, K. Takahashi, D. Elkaffash, M. Sedrak, I. Huhtaniemi, T. Abdel-Al, D. Younan, N. G. Cassuto, D. Bouret, I. Hammoud, Y. Barak, S. Seshadri, M. Bates, G. Vince, D. I. Jones, M. Ben Khalifa, D. Montjean, P. Cohen-Bacrie, F. X. Aubriot, M. Cohen, E. Boudjema, M. C. Magli, A. Crippa, B. Baccetti, A. P. Ferraretti, L. Gianaroli, T. Singer, Q. V. Neri, J. C. Hu, R. Maggiulli, Z. Kollman, E. Rauch, P. N. Schlegel, Z. Rosenwaks, G. D. Palermo, B. Zorn, B. Skrbinc, E. Matos, B. Golob, M. Pfeifer, J. Osredkar, E. Sabanegh, R. K. Sharma, A. Thiyagarajan, A. Agarwal, G. Robin, F. Boitrelle, F. Marcelli, C. Marchetti, V. Mitchell, D. Dewailly, J. M. Rigot, N. Rives, A. Perdrix, A. Travers, J. P. Milazzo, N. Mousset-Simeon, B. Mace, A. Jakab, Z. Molnar, M. Benyo, I. Levai, Z. Kassai, A. Ihan, A. Kopitar, M. Kolbezen, D. Vaamonde, M. E. Da Silva-Grigoletto, J. M. Garcia-Manso, R. Vaamonde-Lemos, S. C. Oehninger, G. Walis, D. Monahan, E. Ermolovich, E. Fadlon, A. Abu Elhija, M. Abu Elhija, E. Lunenfeld, M. Huleihel, M. Costantini-Ferrando, J. C. Y. Hu, J. G. Alvarez, E. Velilla, M. Lopez-Teijon, C. Lopez-Fernandez, H. G. Tempest, F. Sun, E. Ko, P. Turek, R. H. Martin, M. T. Zomeno-Abellan, A. Ramirez, A. Gutierrez-Adan, J. C. Martinez, J. Landeras, J. Ballesta, M. Aviles, M. Ganaiem, S. Binder, A. Meinhardt, L. Sousa, A. Grangeia, F. Carvalho, M. Sousa, A. Barros, C. Sifer, N. Sermondade, E. Hafhouf, C. Poncelet, B. Benzacken, R. Levy, J. P. Wolf, L. Crisol, F. Aspichueta, M. L. Hernandez, A. Exposito, R. Matorras, M. B. Ruiz-Larrea, J. I. Ruiz-Sanz, S. Jallad, F. Atig, H. Ben Amor, A. L. I. Saad, A. Kerkeni, M. Ajina, A. L. I. Othmane, I. Koscinski, L. Ladureau, F. Scarselli, V. Casciani, M. Lobascio, M. G. Minasi, P. Rubino, A. Colasante, L. Arizzi, K. Litwicka, E. Iammarrone, S. Ferrero, C. Mencacci, G. Franco, D. Zavaglia, Z. P. Nagy, E. Greco, S. Ohgi, M. Takahashi, C. Kishi, K. Suga, A. Yanaihara, L. W. Chamley, A. Wagner, and A. N. Shelling

Subjects
Andrology, Reproductive Medicine, Phospholipase C, Point mutation, Rehabilitation, Obstetrics and Gynecology, Identification (biology), Biology, Sperm, Gene, Molecular biology
Published
2010
Full Text
View/download PDF

4. Vaginal progesterone in menopause: Crinone(R) 4% in cyclical and constant combined regimens

Author

C Bulletti, Rui Alberto Ferriani, D. de Ziegler, and L. A.M. Moraes

Subjects
medicine.medical_specialty, Hormone Replacement Therapy, medicine.drug_class, medicine.medical_treatment, Endometrium, medicine, Humans, Adverse effect, Amenorrhea, Progesterone, Gynecology, business.industry, Abnormal bleeding, Uterine Hemorrhage, Rehabilitation, Obstetrics and Gynecology, Estrogens, Hormone replacement therapy (menopause), Middle Aged, medicine.disease, Menopause, Administration, Intravaginal, medicine.anatomical_structure, Reproductive Medicine, Estrogen, Vagina, Female, Intravaginal administration, business, Gels
Abstract

Compliance with hormone replacement therapy (HRT) is notoriously low despite ample documentation of clinical efficacy. The two major reasons given by women who discontinue HRT are uterine bleeding and side-effects. The recent development of a controlled and sustained vaginal progesterone gel allowed single daily application and made prolonged use such as for menopause possible. Here we report our clinical experience with two therapeutic options for HRT using natural progesterone administered vaginally. A first group of 69 menopausal women received the sustained release vaginal progesterone gel, Crinone 4% (45 mg daily) from days 1-10 of each calendar month with oestrogens taken continuously. A second group of 67 women received Crinone 4% twice weekly in conjunction with continuous oestrogen therapy. Endometrial thickness was evaluated before and after 6 months of treatment. Histological verification was obtained in all cases of abnormal bleeding. At 6 months, 63 out of 69 (91.9%) women receiving progesterone cyclically experienced predictable withdrawal bleeding. The vast majority, 54 (80.6%) of 67 women receiving Crinone in constant combined association with oestrogen therapy, remained amenorrhoeic throughout 6 months of therapy. All cases of abnormal bleeding were biopsied and no hyperplasia was seen. Our results indicate that both regimens using the sustained release vaginal progesterone gel controlled bleeding in HRT. Combined with the lower incidence of side-effects characteristic of vaginal progesterone, both vaginal progesterone regimens have the potential of improving HRT compliance.

Published
2000
Full Text
View/download PDF

6. Endometriosis: absence of recurrence in patients after endometrial ablation

Author

C, Bulletti, D, DeZiegler, M, Stefanetti, E, Cicinelli, E, Pelosi, C, Flamigni, and E, Cincinelli

Subjects
Adult, medicine.medical_specialty, medicine.medical_treatment, Uterus, Urology, Endometriosis, Endometrium, Uterine contractility, Dysmenorrhea, Recurrence, medicine, Humans, In patient, Laparoscopy, Menstrual Cycle, Gynecology, medicine.diagnostic_test, business.industry, Rehabilitation, Obstetrics and Gynecology, Epithelial Cells, General Medicine, Ablation, During menstruation, medicine.disease, Surgery, medicine.anatomical_structure, Reproductive Medicine, In utero, Second-Look Surgery, Endometrial ablation, Abdomen, Female, Surgical diagnosis, Stromal Cells, business, Laparoscopic treatment
Abstract

Endometriosis, a very common and debilitating illness, has responded to both medical and surgical treatments, but optimal treatment remains unavailable. This study was planned to determine whether patients with and thosewithout eutopic endometrium differ in the risk that ectopic endometriotic implants will recur. Of 28 women 24 to 40 years of age with at least one child who had a surgical diagnosis of endometriosis after uncontrolled dysmenorrhea, 14 underwent hysteroscopic endometrial ablation (EA). For the procedure, a roller ball was used at 50 watts in the hope of avoiding recurrent abdominal dissemination of endometrial debris. The remaining patients had laparoscopic treatment of endometriosis only, using either bipolar instruments or excision of the implants. Laparoscopy was repeated 2 years later. Nine of 14 patients undergoing EA had no dysmenorrhea 3 months later, and 3 others had significantly less bleeding. Symptoms were appreciably lessened in only 3 of the 14 non-EA group. No retrograde bleeding was seen in EA patients at follow-up laparoscopy, but 9 of the 14 not having EA had significant recurrences. Stromal and epithelial endometrial cells were found within debris in the cul-de-sac in eight patients not having EA. These results support a critical role for removing eutopic endometrium to prevent recurrent endometriosis. The therapeutic key may be to stop the retrograde uterine contractility during menstruation that may be the major cause of recurrence through ectopic endometrial dissemination. Recurrences may result from treatments that are mainly directed to deleting endometriotic implants and to reducing or antagonizing promoters.

Published
2001

7. Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH)

Author

D. de Ziegler, Pierre-Alain Brioschi, R. Fanchin, C Bulletti, and A. S. Jääskeläinen

Subjects
Adult, endocrine system, medicine.medical_specialty, Menotropins, Time Factors, medicine.drug_class, media_common.quotation_subject, Ovarian hyperstimulation syndrome, Controlled ovarian hyperstimulation, Andrology, Follicle-stimulating hormone, Reproductive Techniques, Ovulation Induction, Pregnancy, Internal medicine, Medicine, Humans, Menstrual cycle, media_common, Estradiol, business.industry, Rehabilitation, Estradiol valerate, Obstetrics and Gynecology, Luteinizing Hormone, medicine.disease, Pregnancy rate, Endocrinology, Reproductive Medicine, Female, Gonadotropin, Follicle Stimulating Hormone, business, Luteinizing hormone, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

We have previously observed that exogenous oestradiol can delay the intercycle increase in plasma follicle stimulating hormone (FSH). The increase in plasma FSH that follows discontinuation of exogenous oestradiol peaks after 3 days. We have now studied the possibility of using exogenous oestradiol to synchronize the increase in endogenous FSH with the onset of human menopausal gonadotrophin (HMG) treatment in controlled ovarian hyperstimulation (COH). A total of 30 women aged 35.1+/-6.3 years (mean+/-SD) undergoing ovarian stimulation received 2 mg of oestradiol valerate twice daily starting on day 25 of the previous menstrual cycle until the first Tuesday following menses. Ovarian stimulation was initiated 3 days later. On the last day of oestradiol treatment, plasma oestradiol, FSH and luteinizing hormone (LH) (mean+/-SEM) were 566+/-53 (pmol/l), 3.8+/-0.4 (IU/l) and 5.5+/-0.8 (IU/l) respectively. After 3 days, the FSH and LH (mean+/-SEM) had increased to 6.7+/-0.7 and 6.9+/-0.7 (IU/l) respectively while oestradiol decreased to 251+/-29 (pmol/l). The mean number (+/-SEM) of HMG ampoules used was 25.1+/-2.7 and treatment lasted 11.3+/-0.9 days. Five women became pregnant for a pregnancy rate (ongoing) of 19 (15)%. If all women aged >40 years (six women who did not become pregnant) were excluded from analysis the pregnancy rate (ongoing) was 24 (19%). These results indicate that exogenous oestradiol can safely be used for the synchronization of endogenous and exogenous FSH stimuli in COH. This approach provides the practical advantage of permitting an advanced timing of the onset of COH treatments when gonadotrophin-releasing hormone (GnRH) agonists are not used, which improves treatment convenience for patients and team members alike. Further development of this model may enable control of the onset of natural cycles which may find practical applications for timing assisted reproductive techniques (intrauterine insemination or in-vitro fertilization) in the natural cycle.

Published
1998

8. Electromechanical activities of human uteri during extra-corporeal perfusion with ovarian steroids

Author

C, Bulletti, R A, Prefetto, G, Bazzocchi, R, Romero, P, Mimmi, V, Polli, G A, Lanfranchi, A M, Labate, and C, Flamigni

Subjects
Adult, Perfusion, Estradiol, Ovary, Uterus, Action Potentials, Humans, Female, In Vitro Techniques, Electrodes, Progesterone, Biomechanical Phenomena
Abstract

A new experimental system was designed to study human uterine activities based on the extra-corporeal perfusion of isolated human uteri. Electromechanical activities in the uterine wall were recorded using bipolar silver-silver electrodes, endoluminal pressure catheters and a dedicated acquisition, storage and analytical system. The electrical signals recorded were isolated spikes and rhythmic activities; the last being primarily associated with organized mechanical events. Perfusion media containing 17 beta-oestradiol alone or with progesterone were used for those uteri obtained during proliferative (n = 5) or secretory (n = 5) phases of the menstrual cycle, respectively. Progesterone caused a reduction of frequency (P0.001) and duration (P0.001) of the rhythmic electrical activity, and decreased the endoluminal pressure at both detection sites (P0.01). 17 beta-Oestradiol increased both frequency (P0.001) and duration (P0.001) of the rhythmic electrical activity as well as the endoluminal pressure at two different detection sites (3 and 5 cm from the fundus) (P0.05). Significant differences between the fundus and cervix sites in the uterine wall were detected. In conclusion, uterine perfusion would be useful to examine the effects of uterotonic and tocolytic drugs before administration to humans, at no risk to the patients. Oestrogens increase and progesterone decreases both electrical and mechanical uterine activities.

Published
1993

11. Preface

Author

C. Bulletti and D. de Ziegler

Subjects
Reproductive Medicine, Rehabilitation, Obstetrics and Gynecology
Published
2000
Full Text
View/download PDF

12. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17 beta-estradiol

Author

V M, Jasonni, C, Bulletti, S, Naldi, E, Di Cosmo, F, Cappuccini, and C, Flamigni

Subjects
Adult, Hirsutism, Estradiol, Dehydroepiandrosterone Sulfate, Administration, Oral, Androgen Antagonists, Dehydroepiandrosterone, Middle Aged, Administration, Cutaneous, Sex Hormone-Binding Globulin, Humans, Female, Testosterone, Cyproterone, Cyproterone Acetate
Abstract

Twenty-four hirsute women were treated with an inversal sequential scheme of cyproterone acetate, 50 mg/d by oral route from the 1st to the 15th day of the menstrual cycle, along with 100 micrograms/24 h of 17 beta-estradiol transdermally administered from days 1 to 21, for nine cycles at weekly intervals. The acne and seborrhea as well as hirsutism showed a significant improvement in all subjects studied. The plasma testosterone and dehydroepiandrosterone sulfate decrease from 1.5 +/- 1.3 ng/mL and 6.9 +/- 1.3 micrograms/mL to 0.5 +/- 0.03 ng/mL and 2.7 +/- 1.7 micrograms/mL, respectively. Similar values were observed in subjects with idiopathic hirsutism during the treatment. The metabolic parameters, as well as the plasma levels of sex hormone-binding globulin, appeared unaffected by the therapy. Furthermore, the luteinizing hormone and follicle-stimulating hormone secretion was strongly inhibited from the first cycle of treatment. In conclusion, considering the good clinical results and the avoidance of any hepatic effect, this association should be taken into account in the treatment of hirsutism, especially in case of oral estrogen intolerance.

Published
1991

13. O-153 First uterine pass of radioactive terbutaline in human perfused uterus

Author

V. Polli, F Fraceschetti, A. Albonetti, B de Moustier, S. Rossi, V. Negrini, Gianfranco Bolelli, Stefania Alfieri, E. Giacomucci, D de Ziegler, and C Bulletti

Subjects
Andrology, medicine.medical_specialty, medicine.anatomical_structure, Reproductive Medicine, business.industry, Obstetrics, Terbutaline, medicine, Uterus, Obstetrics and Gynecology, business, medicine.drug
Published
1997
Full Text
View/download PDF

14. [Untitled]

Author

G. Comerci, F. Colombo, and C. Bulletti

Subjects
medicine.medical_specialty, Pregnancy, business.industry, Obstetrics, Obstetrics and Gynecology, Medicine, business, medicine.disease
Published
2005
Full Text
View/download PDF

24. Acknowledgments

Author

E. Gurpide and C. Bulletti

Subjects
History and Philosophy of Science, General Neuroscience, General Biochemistry, Genetics and Molecular Biology
Published
1991
Full Text
View/download PDF

25. [Hypothalamic phospholipid liposomes in the treatment of the climacteric syndrome]

Author

V M, Jasonni, A, Palareti, C, Bulletti, G, Fuschini, S, Naldi, and E, Ricciardelli

Subjects
Adult, Psychiatric Status Rating Scales, Drug Carriers, Estradiol, MMPI, Pituitary Hormones, Anterior, Liposomes, Humans, Female, Middle Aged, Phospholipids, Climacteric
Abstract

Phospholipid liposomes have a dopaminergic effect on the human brain. Changes in prolactin and growth hormone secretion have been observed in humans given phospholipid liposomes. The authors have investigated the therapeutic efficacy of hypothalamic phospholipids in the menopausal syndrome. The study was an open trial on 37 outpatients treated with 1 and 2 ampoules i.m. of a preparation of phospholipids (in the form of unilamellar liposomes) for a period of six months. The therapeutic effects were assessed by means of the Hamilton rating scale, MMPI (Minnesota multiphasic inventory test), and a list of psychosomatic symptoms (LSP). In the patients no change in FSH, LH, PRL, or E2 secretion was observed, whereas the neurotic symptomatology appeared remarkably reduced.

Published
1989

27. Estrone sulphate and estrone splanchnic extraction in postmenopausal women

Author

V M, Jasonni, C, Bulletti, M, Bonavia, F, Franceschetti, P, Ciotti, G, Fuschini, A, De March, L, La Marca, and C, Flamigni

Subjects
Estrone, Radioimmunoassay, Humans, Female, Splanchnic Circulation, Menopause, Middle Aged
Abstract

The splanchnic extraction of estrone sulphate (E1 S) and estrone (E1) was calculated in post-menopausal women undergoing cardiac catheterization for diagnostic purposes. The results showed a net uptake for E1 by the splanchnic area, liver included, whereas the splanchnic extraction of E1 S was not similar for each subject. Anyway the results clearly showed that the splanchnic area does not release significant amount of E1 S into the blood in the post-menopausal women.

Published
1982

29. Extraction of estrogens by human perfused uterus. Effects of membrane permeability and binding by serum proteins on differential influx into endometrium and myometrium

Author

C, Bulletti, V M, Jasonni, P M, Ciotti, S, Tabanelli, S, Naldi, and C, Flamigni

Subjects
Cell Membrane Permeability, Estradiol, Estrone, Uterus, Dextrans, Estrogens, Blood Proteins, Capillary Permeability, Perfusion, Endometrium, Myometrium, Humans, Female, Menstrual Cycle
Abstract

The present study was undertaken to examine the extractions of estradiol, estrone, and estrone sulfate from the circulation of the human perfused uterus. The differential permeability of endometrial and myometrial vascular beds to estrogens was evaluated in uteri samples obtained during the proliferative and secretive phases of the menstrual cycle. The effects of binding by human serum proteins on estrogen influx into the endometrium and myometrium were also determined by the use of double-isotope, single-injection, timed tissue sampling techniques adapted to the extracorporeal perfusion of human uterus. Tritiated test estrogen was injected into the uterine artery as a mixture with 14C-butanol, a free diffusible reference substance. The influx of 14C-dextran (a membrane-impermeable compound) was used to test the aspecific influx from vasculature to extravascular space. Results show that in the human perfused uterus: (1) membrane permeability plays different roles in estrogen influxes between the endometrium and myometrium; (2) during the proliferative and secretive phase of the menstrual cycle the uterine microvessels are differently permeable to the free plus protein-bound estrogens; and (3) plasma proteins decrease the endometrial and myometrial uptakes of estrogens.

Published
1988

30. Diagnostic and therapeutic problems of hyper-prolactinemia in women

Author

C, Flamigni, V M, Jasonni, C, Fuschini, C, Bulletti, P, Montevecchi, and A P, Ferraretti

Subjects
Clinical Laboratory Techniques, Empty Sella Syndrome, Lactation Disorders, Galactorrhea, Luteinizing Hormone, Clomiphene, Prolactin, Levodopa, Pregnancy, Metergoline, Humans, Female, Pituitary Neoplasms, Follicle Stimulating Hormone, Menstruation Disturbances
Published
1980

31. Relative distribution of estrone, estradiol and estriol between fetal and maternal perfusates during perfusions of human term placentas with labelled C19 precursors

Author

Alexander Biener, Seth Guller, Erlio Gurpide, and C Bulletti

Subjects
medicine.medical_specialty, Time Factors, Estrone, Placenta, Biology, In Vitro Techniques, Ethinyl Estradiol, Biochemistry, chemistry.chemical_compound, Endocrinology, In vivo, Pregnancy, Internal medicine, medicine, Distribution (pharmacology), Humans, Tissue Distribution, Androstenedione, Fetus, Estradiol, Estriol, In vitro, Perfusion, chemistry, Female
Abstract

Published results from in vivo experiments carried out in Rhesus monkeys and from in vitro perfusions of human term placentas have indicated that placental estradiol (E2) is preferentially released towards the mother whereas estrone (E1) is about evenly distributed between fetal and maternal circulation. In order to examine the distribution of estriol, relative to that of E1 and E2, we have now prepared [3H]16-hydroxyandrostenedione by incubation of [6,7-3H]androstenedione with Streptomyces roseochromogenus and perfused placental cotyledons with mixtures of these two labeled precursors. Measurement of the concentrations of tritiated E1, E2 and E3 in the maternal and fetal perfusates, flowing at approx 10 and 5 ml/min, respectively, indicated that the distribution of E3 is different from that of E2 and resembles the distribution of E1. The simple perfusion system being used shows differences in the distribution of various estrogens between fetal and maternal perfusates which may reflect the in vivo situation and offers the opportunity for experimental examination of various explanations for these differences, e.g. existence of specific carrier systems in the syncytial membranes, specific binding of the estrogens to secreted placental proteins, and actions of placental and decidual 17β-hydroxysteroid dehydrogenases.

Published
1984

32. Preliminary report on postmenopausal endometrial hyperplasia treatment with Danazol: histological and endocrinological aspects

Author

V M, Jasonni, S, Naldi, L, La Marca, C, Bulletti, P, Ciotti, A, Vignudelli, and C, Flamigni

Subjects
Estrone, Danazol, Pregnadienes, Endometrial Hyperplasia, Humans, Female, Menopause, Middle Aged
Abstract

The synthetic steroid Danazol is commonly used in the hormonal treatment of endometriosis; however, little is known about its effects on human endometrium. This study was performed to verify the efficacy of Danazol on the treatment of endometrial hyperplasia in postmenopausal patients. Ten patients with histologically proven endometrial hyperplasia were treated with Danazol at a dosage of 600 mg/day for 30 days. The E1S and E1 plasma levels were also determined before and at the end of therapy. In all patients the regression of endometrial hyperplasia was observed in the endometrial biopsy specimens obtained after the treatment. Furthermore, the increased E1S/E1 ratio as compared to the basal values suggests an impairment of the peripheral sulfatase activity. The inhibition of the conversion of E1S to active unconjugated estrogens appears to be one of the mechanisms by which Danazol may act on the endometrium.

Published
1986

33. Preliminary report on progesterone effect on peripheral estrone sulfate metabolism

Author

V M, Jasonni, C, Bulletti, F, Franceschetti, P, Ciotti, M, Bonavia, A P, Ferraretti, and C, Flamigni

Subjects
Kinetics, Estrogens, Conjugated (USP), Estradiol, Estrone, Metabolic Clearance Rate, Humans, Female, Middle Aged, Progesterone
Abstract

The effect of progesterone (P) on peripheral estrone sulfate (E1S) was investigated in postmenopausal women using E1S constant infusions. The metabolic clearance rate of E1S (MCRE1S) was significantly lowered by P administration (p less than 0.01), while no significant changes were observed for E1S----E1 conversion ratio. The present findings suggest that P can affect the E1S peripheral fate inducing deep changes in estrogen equilibrium.

Published
1983

34. Increased extraction of estrogens in human endometrial hyperplasia and carcinoma

Author

C, Bulletti, V M, Jasonni, S, Tabanelli, P, Ciotti, F, Cappuccini, A, Borini, and C, Flamigni

Subjects
Perfusion, Endometrium, Estradiol, Estrone, Endometrial Hyperplasia, Uterine Neoplasms, Uterus, Humans, Female, Adenocarcinoma
Abstract

The present study was undertaken to assess in vitro the endometrial extraction of natural estrogens. Normal, hyperplastic, and neoplastic endometria were studied. This was accomplished by the use of double isotope, single-injection techniques performed during the extracorporeal perfusion of human isolated uterus. The differential permeability of vascular beds in normal and neoplastic endometrium to estrogens was evaluated. The effects of binding by human serum proteins on estrogen influx into the endometrium were also determined. When protein-free Ringer's solution was used as an injection vehicle, both normal and abnormal endometrium permitted free diffusion of estradiol (E2), estrone (E1), and estrone sulfate (E1S). In contrast, the endometrial extraction of these estrogens from human female serum was significantly lower than that obtained with Ringer's solution. The extraction of E2, E1, and E1S from human serum was significantly higher in hyperplastic and carcinomatous endometria than in normal proliferative endometria. We conclude that 1) membrane permeability to estrogenic influxes differs between normal and abnormal endometria and 2) plasma proteins decrease the endometrial uptake of estrogens.

Published
1988

35. Danazol reverses endometrial hyperplasia to normal endometrium

Author

C, Bulletti, V M, Jasonni, S, Tabanelli, M, Balducci, G, Fuschini, and C, Flamigni

Subjects
Danazol, Pregnadienes, Endometrial Hyperplasia, Humans, Female, Middle Aged
Abstract

Danazol, an isoxazol derivate of ethinyltestosterone, was used in the treatment of thirtyone postmenopausal patients with endometrial hyperplasia at the dose of 400 mg/day for three months. A profound growth-inhibitory effect of danazol on human endometrium was previously suggested. The present study shows that this compound is effective to reverse the endometrial hyperplasia to normal endometrium in 97% of cases. Atrophic changes of endometrial hyperplasia to normal endometrium after danazol-treatment were observed in 68% of patients. These results strongly suggest that danazol has a significant antiproliferative effect on the endometrium.

Published
1987

36. Estrogen provocation test: lack of correlation between LH and 17-beta-estradiol basal levels and LH peak response in hypothalamic chronic anovulation

Author

V M, Jasonni, C, Bulletti, P, Cristiani, G, Fuschini, A P, Ferraretti, M, Bonavia, and C, Flamigni

Subjects
Adult, Gonadotropin-Releasing Hormone, Estradiol, Hypothalamus, Humans, Estrogens, Female, Luteinizing Hormone, Anovulation
Abstract

Estrogen provocation test was performed in 27 women with hypothalamic chronic anovulation: all patients received I mg of estradiol benzoate (EB) as a single im injection. Plasma 17-beta-estradiol (E2) levels were monitored during the test performed and then compared; no significant correlation was found between mean basal values of LH and E2 and the LH peak response (r = 0.246, P = 0.108 for LH; r = 0.124, P = 0.278 for E2). These data seem to indicate that basal LH values reflect the tonic secretion but not the hypothalamic responsiveness to the estrogen positive feedback; moreover, this latter seems not be influenced by the endogenous E2 levels.

Published
1982

38. Changes in the uterine vasculature during the menstrual cycle

Author

C, Bulletti, V M, Jasonni, S, Tabanelli, P, Ciotti, A, Vignudelli, and C, Flamigni

Subjects
Endometrium, Regional Blood Flow, Uterus, Angiography, Humans, Female, Arteries, Menstruation, Veins
Abstract

The uterine vasculature of 15 uteri, which were hysterectomized for cervical cancer, has been studied. The removed uteri were immediately cannulated with four catheters inserted into the uterine arteries and veins and the vasculature was flushed with a saline-heparin solution. The vessels were clearly visualized by injection of radioopaque medium or of 5-10 ml prevulcanized natural latex, followed by tissue digestion. Histological studies of uterine specimens were also carried out for histomorphologic studies. The results show differences in the architecture of uterine vasculature, related to the cyclic hormonal changes. Most of the modifications occur in the radial and coiled arteries as well as in "venous lakes" of the endometrium.

Published
1985

42. Ovarian surgery for bilateral endometriomas influences age at menopause

Author

Maria Elisabetta Coccia, Carlo Bulletti, Francesca Rizzello, Antonio Palagiano, Gianfranco Scarselli, Giulia Mariani, M.E. Coccia, F. Rizzello, G. Mariani, C. Bulletti, A. Palagiano, and G. Scarselli

Subjects
Adult, Risk, medicine.medical_specialty, medicine.medical_treatment, Endometriosis, Ovary, premature ovarian failure, Primary Ovarian Insufficiency, Cystectomy, cystectomy, Risk Factors, medicine, Humans, Cyst, Prospective Studies, Endometriosi, Laparoscopy, Prospective cohort study, Gynecology, medicine.diagnostic_test, business.industry, endometrioma, Rehabilitation, Age Factors, Obstetrics and Gynecology, Middle Aged, medicine.disease, Premature ovarian failure, Menopause, medicine.anatomical_structure, Reproductive Medicine, Female, business, Follow-Up Studies
Abstract

Background Questions remain as to whether surgical excision of ovarian endometriomas might cause damage to ovarian function. To test the hypothesis that ovarian surgery for endometrioma compromises ovarian function and accelerates ovarian failure. Methods In a tertiary university Clinic, longitudinal prospective cohort study. Patients who underwent laparoscopy for endometriosis between March 1993 and November 2007 were assessed for inclusion in the study. A prospective follow-up at 3, 6 and 12 months then yearly was conducted. Evolution of menstrual pattern, symptoms and reproductive outcomes were investigated. Results From over the 14-year period, 302 patients were included in the study. The mean age (±SD) of patients was 32.6 ± 5.6 years; the median duration of follow-up was 8.5 years (range 2-17 years). Menopause was documented in 43 women (14.3%) at a mean age of 45.3 ± 4.3 years (range 32-52 years). Women previously submitted to bilateral cystectomy were younger at menopause than those with monolateral endometrioma (42.1 ± 5.1 years versus 47.1 ± 3.5 years, P = 0.003). Premature ovarian failure (POF) was observed in 7 of 43 (16.3%) menopausal patients; the majority (4, 57.1%) after bilateral cystectomy. The relationship between the preoperative ovarian endometriomas total diameter and menopausal age was significant in case of surgery for bilateral endometriomas (R(2) = 0.754, P = 0.002). Conclusions Patients who had been operated on for bilateral endometriomas have an increased risk of POF. Ovarian parenchyma loss at the time of surgery seems related to cyst diameter. In the case of unilateral ovarian endometrioma, the contralateral intact ovary might adequately compensate.

Published
2011

43. The artificial uterus: on the way to ectogenesis.

Author

Bulletti FM, Sciorio R, Palagiano A, and Bulletti C

Subjects
Pregnancy, Humans, Female, Embryo Implantation, Ectogenesis, Uterus transplantation
Abstract

The inability to support the growth and development of a mature fetus up to delivery results in significant human suffering. Current available solutions include adoption, surrogacy, and uterus transplantation. However, these options are subject to several ethical, religious, economic, social, and medical concerns. Ectogenesis is the process in which an embryo develops in an artificial uterus from implantation through to the delivery of a live infant. This current narrative review summarizes the state of recent research focused on human ectogenesis. First, a literature search was performed to identify published reports of previous experiments and devices used for embryo implantation in an extracorporeally perfused human uterus. Furthermore, studies fitting that aim were selected and critically evaluated. Results were synthesized, interpreted, and used to design a prospective strategy for future research. Therefore, this study suggests that full ectogenesis might be obtained using a computer-controlled system with extracorporeal blood perfusion provided by a digitally controlled heart-lung-kidney system. From a clinical perspective, patients who will derive significant benefits from this technology are mainly those women diagnosed with anatomical abnormalities of the uterus and those who have undergone previous hysterectomies, numerous abortions, and experienced premature birth. Ectogenesis is the complete development of an embryo in an artificial uterus. It represents the solutions for millions of women suffering from premature deliveries, and the inability to supply growth and development of embryos/fetuses in the womb. In the future, ectogenesis might replace uterine transplantation and surrogacy.

Published
2023
Full Text
View/download PDF

44. Clinical and laboratory key performance indicators in IVF: A consensus between the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) and the Italian Society of Embryology, Reproduction and Research (SIERR).

Author

Vaiarelli A, Zacà C, Spadoni V, Cimadomo D, Conforti A, Alviggi C, Palermo R, Bulletti C, De Santis L, Pisaturo V, Vigiliano V, Scaravelli G, Ubaldi FM, and Borini A

Subjects
Female, Humans, Consensus, Italy, Fertility, Fertilization in Vitro, Reproduction, Infertility therapy, Reproductive Medicine
Abstract

Purpose: Infertility is increasing worldwide, and many couples seek IVF. Clinical management and laboratory work are fundamental in the IVF journey. Therefore, the definition of reliable key performance indicators (KPIs) based on clinical and laboratory parameters, is essential for internal quality control (IQC). Laboratory performance indicators have been identified and a first attempt to also determine clinical ones has been recently published. However, more detailed indicators are required., Methods: An Italian group of experts in Reproductive Medicine from both public and private clinics on behalf of SIFES-MR and SIERR was established to define IVF indicators to monitor clinical performance., Results: The working group built a consensus on a list of KPIs, performance indicators (PIs) and recommendation indicators (RIs). When deemed necessary, the reference population was stratified by woman age, response to ovarian stimulation and adoption of preimplantation genetic testing for aneuploidies (PGT-A). Each indicator was scored with a value from 1 to 5 and a weighted average formula - considering all the suggested parameters-was defined. This formula generates a center performance score, indicating low, average, good, or excellent performance., Conclusion: This study is intended to provide KPIs, PIs and RIs that encompass several essential aspects of a modern IVF clinic, including quality control and constant monitoring of clinical and embryological features. These indicators could be used to assess the quality of each center with the aim of improving efficacy and efficiency in IVF., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

45. Risk of genetic and epigenetic alteration in children conceived following ART: Is it time to return to nature whenever possible?

Author

Sciorio R, Tramontano L, Rapalini E, Bellaminutti S, Bulletti FM, D'Amato A, Manna C, Palagiano A, Bulletti C, and Esteves SC

Subjects
Female, Humans, Child, Reproductive Techniques, Assisted adverse effects, Epigenesis, Genetic, Fertilization, Fertilization in Vitro, Infertility genetics
Abstract

Assisted reproductive technology may influence epigenetic signature as the procedures coincide with the extensive epigenetic modification occurring from fertilization to embryo implantation. However, it is still unclear to what extent ART alters the embryo epigenome. In vivo fertilization occurs in the fallopian tube, where a specific and natural environment enables the embryo's healthy development. During this dynamic period, major waves of epigenetic reprogramming, crucial for the normal fate of the embryo, take place. Over the past decade, concerns relating to the raised incidence of epigenetic anomalies and imprinting following ART have been raised by several authors. Epigenetic reprogramming is particularly susceptible to environmental conditions during the periconceptional period; therefore, unphysiological conditions, including ovarian stimulation, in vitro fertilization, embryo culture, cryopreservation of gametes and embryos, parental lifestyle, and underlying infertility, have the potential to contribute to epigenetic dysregulation independently or collectively. This review critically appraises the evidence relating to the association between ART and genetic and epigenetic modifications that may be transmitted to the offspring., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

46. Progesterone: The Key Factor of the Beginning of Life.

Author

Bulletti C, Bulletti FM, Sciorio R, and Guido M

Subjects
Pregnancy, Female, Humans, Lipopolysaccharides pharmacology, Luteal Phase, Reproductive Techniques, Assisted, Progesterone pharmacology, Beginning of Human Life
Abstract

Progesterone is the ovarian steroid produced by the granulosa cells of follicles after the LH peak at mid-cycle. Its role is to sustain embryo endometrial implantation and ongoing pregnancy. Other biological effects of progesterone may exert a protective function in supporting pregnancy up to birth. Luteal phase support (LPS) with progesterone is the standard of care for assisted reproductive technology. Progesterone vaginal administration is currently the most widely used treatment for LPS. Physicians and patients have been reluctant to change an administration route that has proven to be effective. However, some questions remain open, namely the need for LPS in fresh and frozen embryo transfer, the route of administration, the optimal duration of LPS, dosage, and the benefit of combination therapies. The aim of this review is to provide an overview of the uterine and extra-uterine effects of progesterone that may play a role in embryo implantation and pregnancy, and to discuss the advantages of the use of progesterone for LPS in the context of Good Medical Practice.

Published
2022
Full Text
View/download PDF

47. How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus.

Author

Bulletti C, Allegra A, Mignini Renzini M, and Vaiarelli A

Subjects
Adult, Consensus, Delphi Technique, Dose-Response Relationship, Drug, Expert Testimony statistics & numerical data, Female, Fertility Agents, Female administration & dosage, Humans, Infertility epidemiology, Italy epidemiology, Ovulation Induction statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, Pregnancy, Gonadotropins administration & dosage, Infertility therapy, Ovulation Induction methods
Abstract

Aim: Define how and when fixed starting gonadotropin doses can be used in current clinical ART practices in Italy., Methods: A Delphi conference consisting of three rounds was performed in order to define the ideal clinical conditions in which fixed-gonadotropin-dose during COS should be applied. During the conference, 19 statements about the current ART practice were provided to a panel of twenty-nine national experts. Median score was 5 (IQ:4-6) in all Delphi rounds., Results: Eleven statements (57.9%) were classified as shareable with high-degree of convergence, 2 (10.5%) as shareable with low convergence and 6 (31.6%) as un-shareable with high convergence. The panel reached high consensus regarding some statements: (i) fixed FSH-dose in normoresponders and poor-responder, (ii) importance of predicting ovarian response before COS, considering multiple markers to select the right stimulation protocol for each patient, (iii) importance of therapy simplification and standardization to improve efficiency during COS. Moreover, a low-convergence was reached about use of GnRH antagonist as first treatment line and drug storage at room temperature. However from these findings, the debate remains open regarding some other statements: (a) usefulness of Bologna-criteria to define poor-responders; (b) efficacy to change always stimulation protocol after a failure IVF; (c) utility of AMH-dosed with standardized automatic mode to define normo-responder patients; (d) usefulness to modify the dosage of 12.5 IU/die during COS to improve stimulation effectiveness., Conclusion: Controlled ovarian stimulation remains a challenging clinical step in Assisted Reproductive Technique, especially in some specific patient groups for which no clinical consensus is available. This study is the first attempt to describe the shared clinical opinion regarding the fixed versus variable gonadotropin dose in the real IVF practice.

Published
2021
Full Text
View/download PDF

48. COVID-19 and ART: the view of the Italian Society of Fertility and Sterility and Reproductive Medicine.

Author

Vaiarelli A, Bulletti C, Cimadomo D, Borini A, Alviggi C, Ajossa S, Anserini P, Gennarelli G, Guido M, Levi-Setti PE, Palagiano A, Palermo R, Savasi V, Pellicer A, Rienzi L, and Ubaldi FM

Subjects
COVID-19, Female, Humans, Infertility, Italy, Pregnancy, Coronavirus Infections, Pandemics, Pneumonia, Viral, Reproductive Techniques, Assisted
Abstract

The COVID-19 pandemic is an unprecedented global situation. As assisted reproductive technology (ART) specialists, we should be cautious, carefully monitoring the situation while contributing by sharing novel evidence to counsel our patients, both pregnant women and would-be mothers. Time to egg collection and drop-out rates are critical parameters for scheduling treatments once the curve of infections has peaked and plateaued in each country. In order to reduce the values for these two parameters, infertile patients now require even more support from their IVF team: urgent oocyte collection for oncology patients must be guaranteed, and oocyte retrievals for women of advanced maternal age and/or reduced ovarian reserve cannot be postponed indefinitely. This document represents the position of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) in outlining ART priorities during and after this emergency., (Copyright © 2020 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)

Published
2020
Full Text
View/download PDF

50. Assisted reproduction in endometriosis.

Author

de Ziegler D, Pirtea P, Carbonnel M, Poulain M, Cicinelli E, Bulletti C, Kostaras K, Kontopoulos G, Keefe D, and Ayoubi JM

Subjects
Adult, Endometriosis complications, Female, Humans, Infertility, Female etiology, Ovarian Diseases complications, Ovarian Reserve physiology, Pregnancy, Endometriosis therapy, Infertility, Female therapy, Ovarian Diseases therapy, Reproductive Techniques, Assisted
Abstract

Endometriosis - a disease causing pain and infertility - is encountered in nearly 50% of infertile women. While medical treatment is effective on pain and recurrence of symptoms after surgical excision, it is of no help for treating infertility for which the only options considered are surgery and ART. Surgery enhances the chances of conceiving naturally during the 12-18 ensuing months irrespective of the stage of the disease. Surgery however is of no help when ART is considered, as it does not improve outcome and can only harm the ovarian response to stimulation. Today therefore, ART is commonly the primary option to be considered in women whose infertility is associated with endometriosis and whose ovarian reserve is compromised and/or who are over 35 years of age. When, ART is envisioned it is best to opt for a segmented ART approach with agonist trigger, freeze all and deferred embryo transfer., (Copyright © 2018 Elsevier Ltd. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results